Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio
Acquisition Details:
Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in cash, totaling approximately $14.6 billion45.
Portfolio Enhancement:
The acquisition includes CAPLYTA (lumateperone), a treatment for bipolar I and II depression and schizophrenia, and ITI-1284, a Phase 2 compound for generalized anxiety disorder and Alzheimer's disease-related psychosis and agitation4.
Strategic Impact:
The deal strengthens Johnson & Johnson's neuroscience leadership and adds significant growth potential, with CAPLYTA expected to achieve peak year sales of over $5 billion4.
Transaction Timeline:
The closing of the transaction is expected to occur later in 2025, subject to regulatory approvals and other customary conditions4.
Financial Impact:
Johnson & Johnson will fund the transaction through a combination of cash on hand and debt, maintaining a strong balance sheet and supporting its capital allocation priorities4.
Sources:
4. https://www.globenewswire.com/news-release/2025/01/13/3008254/0/en/Johnson-Johnson-Strengthens-Neuroscience-Leadership-with-Acquisition-of-Intra-Cellular-Therapies-Inc.html